Rossari Biotech

Mumbai, India Founded: 1997 • Age: 29 yrs Listed
Manufacturer of textile and specialty chemicals for diverse industries and animal health nutrition products
Request Access
Report Incorrect Data
Page last updated

About Rossari Biotech

Rossari Biotech is a publicly listed company based in Mumbai (India) founded in 1997 by Edward Menezes. The company has 1,270 employees. Rossari Biotech has completed 2 acquisitions, including Tristar Intermediates and Unitop Chemicals. Its chief executive, as recorded, is Puneet Arora. Its website rossari.com draws about 24 thousand monthly visits. Its Indian entity Rossari Biotech Limited reported revenue of ₹2,421 Cr. Rossari Biotech offers products and services including Specialty Chemicals, Textile Specialty Chemicals, and Animal Health Products. Its focus areas include Chemicals and Materials, Diversified Chemicals and Speciality Chemicals.

Company details

Manufacturer of textile and specialty chemicals for diverse industries and animal health nutrition products. Its products including home, personal care, performance chemicals, animal health, and nutrition. It offers customized solutions to industrial and production requirements through a diversified product portfolio. The companys expertise extends to surfactants, specialty chemicals, and functional finishes. A focus on sustainable products and solutions is a key aspect of its operations.

Recognitions & Rankings of Rossari Biotech

India's Most Valuable Companies 2021 edition · Source: Hurun India
Rank#405
Valuation
₹7,520 Cr
  • Headquarters Mumbai, India
  • Employees 1,270
  • Founders Edward Menezes
  • Stage Public
  • Sectors
    Chemicals & Materials
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website rossari.com
  • Social LinkedIn X Facebook Instagram
  • Legal Name Rossari Biotech Ltd
Operational Areas
Chemicals & Materials → Core & Diversified Chemicals
Key Metrics
  • Market Cap
    ₹2,256 Cr

    ROSSARI · NSE

  • Share Price
    ₹420.40

    +3.20% today

  • Revenue
    ₹2,396 Cr

    FY 2025-26 · +15.2% YoY

  • EBITDA
    ₹286 Cr

    Margin 11.9%

  • Net Profit
    ₹136 Cr

    FY 2025-26 · -0.6% YoY

  • P/E (TTM)
    14.7x

    P/B 1.6x

  • ROE
    11.8%

    ROCE 14.5%

  • Debt / Equity
    0.26

    Interest cover 13.8x

  • Investors
    Department of Biotechnology
  • Employee Count
    1,270
  • Investments & Acquisitions
    Tristar Intermediates

    & 1 more

Products & Services of Rossari Biotech

Rossari Biotech offers a comprehensive portfolio of products and services, including Specialty Chemicals, Textile Specialty Chemicals, and Animal Health Products.

Specialty Chemicals
Chemical Manufacturing

Provides customized solutions for industrial applications

Textile Specialty Chemicals
Textile Chemicals

Chemicals for cotton, polyester, and functional finishes

Animal Health Products
Nutrition Supplements

Supplies vitamins and enzymes for poultry and pet care

Funding Insights of Rossari Biotech

  • Total Rounds 1
  • Investors Count 1

All 1 funding rounds of Rossari Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2012Grant––
Department of Biotechnology
Valuation history

1 investors in total: 1 institutional.

Investors in Rossari Biotech

Rossari Biotech has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Department of Biotechnology.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Department of Biotechnology
Biotechnology research, guidelines, and funding by the Government of India.
1986dbtindia.gov.inDelhi, India
Premium access

Investor details for Rossari Biotech

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Rossari Biotech Limited (Rossari Biotech)

Rossari Biotech Limited is the primary company behind Rossari Biotech. The boards of the 2 registered companies of Rossari Biotech currently have 9 directors; the longest-serving is Sanjay Ramakrishna Marballi, appointed in 1997. 18 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sanjay Ramakrishna Marballi
DIN 00002476
Whole-time director01 Sep 199729 yrs 2 moTristar Intermediates Private Limited
Aseem Dhru
DIN 01761455
Director12 Nov 20196 yrs 11 moRossari Biotech Limited
Sunil Srinivasan Chari
DIN 00149083
Director01 Sep 20215 yrs 2 moTristar Intermediates Private Limited, Rossari Biotech Limited
Mikhail Menezes
DIN 02789957
Director01 Sep 20215 yrs 2 moTristar Intermediates Private Limited
Yash Sunil Chari
DIN 08805529
Director01 Sep 20215 yrs 2 moTristar Intermediates Private Limited
Edward Walter Menezes
DIN 00149205
Director01 Sep 20215 yrs 2 moTristar Intermediates Private Limited, Rossari Biotech Limited
Gurudas Vishwas Aras
DIN 02187903
Director22 Nov 20214 yrs 11 moTristar Intermediates Private Limited, Rossari Biotech Limited
Esha Padmanabhan Achan
DIN 10350369
Director21 Oct 20233 yrsRossari Biotech Limited
Udeypaul Singh Gill
DIN 00004340
Director28 Apr 20266 moRossari Biotech Limited

People of Rossari Biotech

15 people are tracked at Rossari Biotech (12 in leadership, 3 in team); the tracked headcount is 1,270.

NameRoleGroup
Edward Menezes
Founder & Co-DirectorLeadership
Yash Chari
Director – Marketing and Business DevelopmentLeadership
Mikhail Menezes
Director – TechnicalLeadership
Puneet Arora
CEOLeadership
Madan Ekbote
CEOLeadership
Ashok Kumar Chouhan
Director OperationsLeadership
Rajeev Jha
Vice President - Home - Personal Care & Performance ChemicalsLeadership
Sandeep Tulshyan
Head - Global Projects & Supply ChainLeadership
Abir Banerjee
Senior Vice President Head Engineering & ProjectsLeadership
Shantanu Dey
Vice President- Exports & BrandLeadership
Dewang Garg
President OperationsLeadership
Neetha Thomas
Head - Corporate HRLeadership
Abhishek Gupta
Zonal Business ManagerTeam
Hemant Kumar Pandey
National Sales ManagerTeam
Namita Kambli
Export ManagerTeam
Premium access

Complete people profiles for Rossari Biotech

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Rossari Biotech

Rossari Biotech is a publicly listed company on the NSE with ticker symbol ROSSARI in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date23 Jul 2020
  • Listed onNSE: ROSSARI · BSE: 543213
  • Listed entityRossari Biotech Ltd
  • Exchange sectorProcess industries
  • ISININE02A801020
  • Share price₹431.00 (+1.01% on the day) · 2026-10-14
  • Market capitalisation₹2,372 Cr
  • Price to earnings15.9
  • EPS (diluted, trailing year)₹27.18
  • Dividend yield0.12%
  • Volume (last session)24,179

Financials of Rossari Biotech

Exchange-reported figures of Rossari Biotech Limited, the listed company behind Rossari Biotech (NSE: ROSSARI).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,396 Cr
+15.2% YoY
EBITDA
₹286 Cr
+7.9% YoY
Profit After Tax
₹136 Cr
-0.6% YoY
Net Worth
₹1,333 Cr
+12.5% YoY
Total Assets
₹1,778 Cr
+26.2% YoY
Total Debt
₹436 Cr
+100.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,3962,0801,8311,6561,483709600
Revenue growth+15.2%+13.6%+10.6%+11.7%+109.1%+18.2%-
EBITDA286265250223183124105
EBITDA margin+11.9%+12.7%+13.6%+13.5%+12.4%+17.4%+17.4%
Profit before tax20318517814413610787.83
Net profit13613612910797.2379.8865.30
Net profit margin+5.7%+6.6%+7.1%+6.5%+6.6%+11.3%+10.9%
EPS (₹)26.9424.6323.6619.4517.7415.4512.86
Balance sheet
Total assets1,7781,4091,170999902410355
Net worth1,3331,1851,048915805409287
Total debt43621811973.938.430.0066.93
Cash & bank92.2157.1630.2112452.3588.26127
Net working capital733544456385312205197
Cash flow
Cash from operations65.0713743.2615229.3647.7756.83
Cash from investing(220)(183)(103)(181)(299)(37.18)(190)
Cash from financing18664.9016.1960.86292(24.59)157
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue698697685582586544580513
Revenue growth (YoY)+19.0%+28.2%+18.2%+13.5%+17.6%+11.0%--
Other income1.073.6419.580.912.071.721.940.88
EBITDA86.9780.6277.2568.8771.9367.8669.4964.76
EBITDA margin+12.5%+11.6%+11.3%+11.8%+12.3%+12.5%+12.0%+12.6%
Depreciation30.1025.6223.5319.6118.2317.7518.2218.32
Interest8.6810.989.067.676.095.735.504.94
Profit before tax49.2647.6664.2442.5049.6846.1047.7142.38
Tax10.3612.5718.289.7312.7912.5113.2610.67
Net profit38.9035.0945.9632.7736.8933.5934.4531.71
EPS (₹)7.026.338.295.916.656.066.215.72
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,7521,4321,2039751,073690600
Revenue growth+22.4%+19.0%+23.4%-9.1%+55.4%+15.1%-
EBITDA208186161123123121105
EBITDA margin+11.9%+13.0%+13.4%+12.6%+11.5%+17.6%+17.5%
Profit before tax19115513495.6410710688.11
Net profit12811497.4670.9678.0478.7765.58
Net profit margin+7.3%+7.9%+8.1%+7.3%+7.3%+11.4%+10.9%
EPS (₹)25.7920.7218.0412.9414.4415.2312.91
Balance sheet
Total assets1,3681,1301,030925786405352
Net worth1,2181,077960859785404283
Total debt14449.6968.0264.910.000.0066.93
Cash & bank51.8516.0225.6780.2734.8185.98127
Net working capital472331278249219201196
Cash flow
Cash from operations58.7392.2073.9211333.1252.0955.75
Cash from investing(102)(69.57)(69.78)(160)(318)(37.00)(187)
Cash from financing79.13(32.27)(22.09)61.21297(29.45)155
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue495482516451420366427368
Revenue growth (YoY)+18.1%+31.9%+21.0%+22.4%+24.9%+21.6%--
Other income1.692.1922.731.141.401.742.401.01
Total expenses438426453400369322374318
EBITDA57.2856.4263.6050.3850.4143.9552.2049.96
EBITDA margin+11.6%+11.7%+12.3%+11.2%+12.0%+12.0%+12.2%+13.6%
Depreciation10.738.348.977.477.347.157.667.43
Interest2.083.843.813.952.493.093.082.28
Profit before tax46.1646.4373.5540.1041.9835.4543.8641.26
Tax11.9212.1618.829.4710.739.2111.4910.63

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 04 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue698697685582586544580513
Revenue growth (YoY)+19.0%+28.2%+18.2%+13.5%+17.6%+11.0%--
Other income1.073.6419.580.912.071.721.940.88
EBITDA86.9780.6277.2568.8771.9367.8669.4964.76
EBITDA margin+12.5%+11.6%+11.3%+11.8%+12.3%+12.5%+12.0%+12.6%
Depreciation30.1025.6223.5319.6118.2317.7518.2218.32
Interest8.6810.989.067.676.095.735.504.94
Profit before tax49.2647.6664.2442.5049.6846.1047.7142.38
Tax10.3612.5718.289.7312.7912.5113.2610.67
Net profit38.9035.0945.9632.7736.8933.5934.4531.71
EPS (₹)7.026.338.295.916.656.066.215.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,3962,0801,8311,6561,483709600
Revenue growth+15.2%+13.6%+10.6%+11.7%+109.1%+18.2%-
Other income24.284.997.626.4413.549.123.72
Total expenses2,1101,8151,5811,4331,300586496
Employee cost15513210398.6267.9341.9837.21
EBITDA286265250223183124105
EBITDA margin+11.9%+12.7%+13.6%+13.5%+12.4%+17.4%+17.4%
Depreciation79.1267.0760.3962.9348.0622.8316.85
Interest28.5417.8119.3722.3212.662.993.56
Profit before tax20318517814413610787.83
Tax53.3048.8146.9336.9638.5826.7922.58
Net profit13613612910797.2379.8865.30
Net profit margin+5.7%+6.6%+7.1%+6.5%+6.6%+11.3%+10.9%
EPS (₹)26.9424.6323.6619.4517.7415.4512.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.0811.0711.0511.0311.0110.3910.15
Reserves & surplus1,3221,1741,037904794398277
Shareholders' funds (net worth)1,3331,1851,048915805409287
Minority interest0.000.000.000.000.000.000.00
Secured loans40818810663.950.000.0041.82
Unsecured loans27.9530.0312.979.988.430.0025.11
Total debt43621811973.938.430.0066.93
Total liabilities1,7781,4091,170999902410355
Assets
Gross block1,133878791743704234122
Net block78459857858560718193.54
Capital work in progress17314047.2116.081.340.3221.75
Investments62.2983.8062.8651.1735.920.0017.91
Inventories40535528218819095.3558.17
Sundry debtors55747442535430514494.14
Cash & bank balances92.2157.1630.2112452.3588.26127
Loans & advances14797.8768.3328.1450.6127.0333.06
Total current assets1,201985806694598355313
Total current liabilities468441350310286150116
Net working capital733544456385312205197
Total assets1,7781,4091,170999902410355
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash44.2025.1769.2037.4815.2129.215.74
Net cash from operating activities65.0713743.2615229.3647.7756.83
Net cash from investing activities(220)(183)(103)(181)(299)(37.18)(190)
Net cash from financing activities18664.9016.1960.86292(24.59)157
Net change in cash31.1119.03(44.03)31.7222.27(14.00)23.47
Closing cash92.2157.1630.2112452.3588.26127
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+15.2%+13.6%+10.6%+11.7%+109.1%+18.2%-
EBITDA growth+7.9%+6.1%+12.0%+21.6%+48.5%+18.2%-
PBT growth+9.4%+4.3%+23.2%+5.8%+27.6%+21.6%+38.6%
Net income growth-0.6%+5.4%+20.9%+10.1%+21.7%+22.3%-
Revenue CAGR (3Y)+13.1%+11.9%+37.2%+40.3%+42.2%--
EBITDA CAGR (3Y)+8.6%+13.1%+26.5%+28.7%+33.2%--
Profitability & leverage
Net income margin+6.2%+6.6%+7.1%+6.5%+6.6%+11.3%+10.9%
Return on capital employed+14.5%+15.7%+18.2%+17.5%+22.7%+28.7%+37.4%
Return on net worth+11.9%+12.2%+13.3%+12.5%+16.1%+23.0%+31.8%
Debt / equity0.260.150.100.050.010.100.18
Long-term debt / equity0.090.070.040.020.000.050.08
Interest cover13.808.9910.2313.949.352.974.06
Efficiency & per share
Fixed asset turnover2.382.492.392.293.163.985.75
Inventory turnover6.316.537.788.7510.409.2410.61
Debtors turnover4.644.624.705.036.615.966.67
EPS (₹)26.9424.6323.6619.4517.7415.4512.86
Dividend per share (₹)0.500.500.500.500.500.500.50
Book value per share (₹)240.74214.12189.65165.93146.2578.7256.48
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue495482516451420366427368
Revenue growth (YoY)+18.1%+31.9%+21.0%+22.4%+24.9%+21.6%--
Other income1.692.1922.731.141.401.742.401.01
Total expenses438426453400369322374318
EBITDA57.2856.4263.6050.3850.4143.9552.2049.96
EBITDA margin+11.6%+11.7%+12.3%+11.2%+12.0%+12.0%+12.2%+13.6%
Depreciation10.738.348.977.477.347.157.667.43
Interest2.083.843.813.952.493.093.082.28
Profit before tax46.1646.4373.5540.1041.9835.4543.8641.26
Tax11.9212.1618.829.4710.739.2111.4910.63
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,7521,4321,2039751,073690600
Revenue growth+22.4%+19.0%+23.4%-9.1%+55.4%+15.1%-
Other income27.015.746.773.6012.709.723.63
Total expenses1,5441,2451,042853950569495
Employee cost69.4660.0151.4657.3543.5336.6637.13
EBITDA208186161123123121105
EBITDA margin+11.9%+13.0%+13.4%+12.6%+11.5%+17.6%+17.5%
Depreciation30.9327.6924.1925.9826.2722.0716.85
Interest13.359.589.704.622.552.993.68
Profit before tax19115513495.6410710688.11
Tax48.2339.9634.4924.2627.2126.9022.58
Net profit12811497.4670.9678.0478.7765.58
Net profit margin+7.3%+7.9%+8.1%+7.3%+7.3%+11.4%+10.9%
EPS (₹)25.7920.7218.0412.9414.4415.2312.91
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.0811.0711.0511.0311.0110.3910.15
Reserves & surplus1,2071,066949848774394273
Shareholders' funds (net worth)1,2181,077960859785404283
Secured loans12730.1455.0554.930.000.0035.90
Unsecured loans17.7219.5512.979.980.000.0031.03
Total debt14449.6968.0264.910.000.0066.93
Total liabilities1,3681,1301,030925786405352
Assets
Gross block388323283256251220122
Net block21817916715717717193.54
Capital work in progress10534.0924.6013.680.840.3221.75
Investments5485385284933819.2515.21
Inventories18017915111310788.5258.17
Sundry debtors51837530224418113793.81
Cash & bank balances51.8516.0225.6780.2734.8185.98127
Loans & advances11882.2150.5012.4535.8527.6932.96
Total current assets868652529449359340312
Total current liabilities396321251200140139116
Net working capital472331278249219201196
Total assets1,3681,1301,030925786405352
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.9122.5540.5026.7414.8329.195.73
Net cash from operating activities58.7392.2073.9211333.1252.0955.75
Net cash from investing activities(102)(69.57)(69.78)(160)(318)(37.00)(187)
Net cash from financing activities79.13(32.27)(22.09)61.21297(29.45)155
Net change in cash35.74(9.64)(17.95)13.7611.91(14.36)23.46
Closing cash51.8516.0225.6780.2734.8185.98127
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+22.4%+19.0%+23.4%-9.1%+55.4%+15.1%-
EBITDA growth+11.9%+15.5%+31.5%-0.1%+1.2%+15.5%-
PBT growth+23.5%+15.3%+40.3%-10.3%+0.6%+20.3%+38.9%
Net income growth+12.5%+16.5%+37.3%-9.1%-0.9%+20.1%-
Revenue CAGR (3Y)+21.6%+10.1%+20.3%+17.6%+27.6%+33.3%+37.0%
EBITDA CAGR (3Y)+19.3%+14.9%+10.0%+5.3%+16.5%+39.2%+62.4%
Profitability & leverage
Net income margin+8.2%+8.0%+8.3%+7.3%+7.4%+11.5%+10.9%
Return on capital employed+14.7%+15.2%+14.7%+11.7%+18.3%+28.8%+38.0%
Return on net worth+11.1%+11.3%+11.0%+8.7%+13.4%+23.0%+32.5%
Debt / equity0.080.060.070.040.000.100.19
Long-term debt / equity0.020.030.040.020.000.050.09
Interest cover7.526.047.084.782.643.014.17
Efficiency & per share
Fixed asset turnover4.934.724.463.844.554.035.75
Inventory turnover9.778.689.118.8510.959.4110.61
Debtors turnover3.924.234.414.596.745.976.69
EPS (₹)25.7920.7218.0412.9414.4415.2312.91
Dividend per share (₹)0.500.500.500.500.500.500.50
Book value per share (₹)220.00194.56173.83155.69142.5077.8855.85

Investments & Acquisitions by Rossari Biotech

Rossari Biotech has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Tristar Intermediates and Unitop Chemicals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Tristar Intermediates
Perfumery and specialty chemicals are manufactured and supplied.
tristarintermediates.orgThane, India1997Jul 2021$16.06M
Unitop Chemicals
Surfactants and emulsifiers are manufactured for industrial applications.
unitopchemicals.comMumbai, India1980Jun 2021$49.69M
Premium access

Complete acquisition details for Rossari Biotech

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Rossari Biotech

5 dated milestones of Rossari Biotech across 24 years, from founding to its latest funding, stage changes and deals.

  1. Founded Rossari Biotech is founded.
  2. Funding First funding round.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Unitop Chemicals.
  5. Acquisition Acquires Tristar Intermediates.

Web traffic of Rossari Biotech

The website of Rossari Biotech (rossari.com) receives about 24.5K visits a month.

  • Monthly visits
    24.5K

    ▼ 18.2% vs previous month

Similar websites

Websites whose visitors overlap most with Rossari Biotech. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Unitop Chemicals
unitopchemicals.com
100%
1.7K#11,070,275View details
Lumis Biotech
lumisbiotech.com
98%
View details
JAY Chemical Industries
jaychemical.com
95%
3.3K#5,436,042View details
youhaodye.com
youhaodye.com
90%
–
huacaichem.com
huacaichem.com
90%
–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 21 similar websites and full traffic analytics for Rossari Biotech

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 21 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Core & Diversified Chemicals

3 companies that operate in the same segment as Rossari Biotech (Core & Diversified Chemicals) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
DFPCL
Manufacturer of fertilizers, industrial chemicals, crop nutrition products, and real estate
1979Pune, Maharashtra, IndiaUSD 1.21 B1,020
Scimplify
Specialty chemicals are manufactured through integrated R&D and production processes.
2023Bengaluru, Karnataka, IndiaUSD 72.97 MUSD 23.86 M
Himadri Chemicals and Industries
Manufactures coal tar and basic industrial chemicals.
1987Kolkata, West Bengal, IndiaUSD 24 MUSD 515.01 M1,161
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Rossari Biotech

Rossari Biotech: Anticipates Achieving Debt-Free Status In The Coming Months.
Exchange Update • 16 days ago
Buy Rossari Biotech; target of Rs 605: ICICI Securities
Moneycontrol • 3 months ago
ROSSARI: Record quarterly revenue and EBITDA, with margin improvement expected as B2C exits progress
Quartr • 3 months ago
ROSSARI: Record Q1 FY27 revenue up 28% YoY, with robust growth in all core segments and global expansion
Quartr • 3 months ago
Rossari Biotech expects growth to pick up as new capacity comes online - CNBC TV18
CNBCTV18 • 3 months ago
ROSSARI: Q1 FY27 saw higher revenue and profit, new ESOP grants, and internal group restructuring
Quartr • 3 months ago
Rossari Biotech consolidated net profit rises 4.46% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 3 months ago
Buy Rossari Biotech; target of Rs 570: ICICI Direct
Moneycontrol • 6 months ago
ROSSARI: Record revenue and EBITDA in FY26, with strong core segment growth and expanded capacity
Quartr • 6 months ago
ROSSARI: Record FY 2026 revenue and EBITDA, with 15% growth and strong outlook for FY 2027
Quartr • 6 months ago
Premium access

Complete news archive for Rossari Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rossari Biotech

Rossari Biotech was founded in 1997 and raised its 1st funding round 15 years after it was founded.

Rossari Biotech is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Puneet Arora is the CEO of Rossari Biotech, as recorded in our data.

Rossari Biotech has 1,270 employees.

The primary company behind Rossari Biotech, Rossari Biotech Limited, reported revenue of ₹2,421 Cr for FY 2026, up 15% year on year.

Manufacturer of textile and specialty chemicals for diverse industries and animal health nutrition products. Its products including home, personal care, performance chemicals, animal health, and nutrition. It offers customized solutions to industrial and production requirements through a diversified product portfolio. The companys expertise extends to surfactants, specialty chemicals, and functional finishes. A focus on sustainable products and solutions is a key aspect of its operations.

Rossari Biotech offers Specialty Chemicals, Textile Specialty Chemicals, and Animal Health Products.

Yes, Rossari Biotech is publicly traded on NSE under the ticker symbol ROSSARI.

Rossari Biotech has made 2 acquisitions, including Tristar Intermediates, and Unitop Chemicals.

Rossari Biotech has 1 investor. Key investors include Department of Biotechnology.

Rossari Biotech is associated with 2 legal entities: Rossari Biotech Limited, Tristar Intermediates Private Limited.

The legal entities of Rossari Biotech currently have 11 directors, including Sanjay Ramakrishna Marballi, Sunil Srinivasan Chari, Mikhail Menezes and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available